Logo image of CYTK

CYTOKINETICS INC (CYTK) Stock Fundamental Analysis

USA - NASDAQ:CYTK - US23282W6057 - Common Stock

59.62 USD
-0.41 (-0.68%)
Last: 11/4/2025, 8:14:52 PM
58.7 USD
-0.92 (-1.54%)
After Hours: 11/4/2025, 8:14:52 PM
Fundamental Rating

2

Taking everything into account, CYTK scores 2 out of 10 in our fundamental rating. CYTK was compared to 534 industry peers in the Biotechnology industry. Both the profitability and financial health of CYTK have multiple concerns. CYTK is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CYTK has reported negative net income.
CYTK had a negative operating cash flow in the past year.
In the past 5 years CYTK always reported negative net income.
In the past 5 years CYTK reported 4 times negative operating cash flow.
CYTK Yearly Net Income VS EBIT VS OCF VS FCFCYTK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M

1.2 Ratios

Looking at the Return On Assets, with a value of -49.47%, CYTK is in line with its industry, outperforming 51.12% of the companies in the same industry.
Industry RankSector Rank
ROA -49.47%
ROE N/A
ROIC N/A
ROA(3y)-48.08%
ROA(5y)-38.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CYTK Yearly ROA, ROE, ROICCYTK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

CYTK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYTK Yearly Profit, Operating, Gross MarginsCYTK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

CYTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
CYTK has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CYTK has more shares outstanding
CYTK has a better debt/assets ratio than last year.
CYTK Yearly Shares OutstandingCYTK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CYTK Yearly Total Debt VS Total AssetsCYTK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

Based on the Altman-Z score of -1.38, we must say that CYTK is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.38, CYTK perfoms like the industry average, outperforming 52.62% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.38
ROIC/WACCN/A
WACC8.43%
CYTK Yearly LT Debt VS Equity VS FCFCYTK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

2.3 Liquidity

CYTK has a Current Ratio of 6.76. This indicates that CYTK is financially healthy and has no problem in meeting its short term obligations.
CYTK has a Current ratio of 6.76. This is in the better half of the industry: CYTK outperforms 68.73% of its industry peers.
CYTK has a Quick Ratio of 6.76. This indicates that CYTK is financially healthy and has no problem in meeting its short term obligations.
CYTK has a better Quick ratio (6.76) than 68.73% of its industry peers.
Industry RankSector Rank
Current Ratio 6.76
Quick Ratio 6.76
CYTK Yearly Current Assets VS Current LiabilitesCYTK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 4.47% over the past year.
The Revenue has grown by 2633.99% in the past year. This is a very strong growth!
Measured over the past years, CYTK shows a decrease in Revenue. The Revenue has been decreasing by -7.24% on average per year.
EPS 1Y (TTM)4.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.5%
Revenue 1Y (TTM)2633.99%
Revenue growth 3Y-35.98%
Revenue growth 5Y-7.24%
Sales Q2Q%26714.86%

3.2 Future

CYTK is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.00% yearly.
CYTK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 243.66% yearly.
EPS Next Y-8.98%
EPS Next 2Y-4.92%
EPS Next 3Y9.27%
EPS Next 5Y19%
Revenue Next Year2503.25%
Revenue Next 2Y553.56%
Revenue Next 3Y389.93%
Revenue Next 5Y243.66%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CYTK Yearly Revenue VS EstimatesCYTK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
CYTK Yearly EPS VS EstimatesCYTK Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CYTK. In the last year negative earnings were reported.
Also next year CYTK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYTK Price Earnings VS Forward Price EarningsCYTK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYTK Per share dataCYTK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.92%
EPS Next 3Y9.27%

More info and screens

0

5. Dividend

5.1 Amount

CYTK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYTOKINETICS INC

NASDAQ:CYTK (11/4/2025, 8:14:52 PM)

After market: 58.7 -0.92 (-1.54%)

59.62

-0.41 (-0.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners116.32%
Inst Owner Change-1.34%
Ins Owners0.45%
Ins Owner Change-0.8%
Market Cap7.13B
Revenue(TTM)85.74M
Net Income(TTM)-606311000
Analysts80
Price Target78.6 (31.83%)
Short Float %12.11%
Short Ratio5.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.82%
Min EPS beat(2)1.37%
Max EPS beat(2)20.28%
EPS beat(4)2
Avg EPS beat(4)2.82%
Min EPS beat(4)-6.82%
Max EPS beat(4)20.28%
EPS beat(8)2
Avg EPS beat(8)-17.77%
EPS beat(12)2
Avg EPS beat(12)-17.91%
EPS beat(16)4
Avg EPS beat(16)-6.59%
Revenue beat(2)2
Avg Revenue beat(2)1337.63%
Min Revenue beat(2)28.69%
Max Revenue beat(2)2646.57%
Revenue beat(4)3
Avg Revenue beat(4)866.58%
Min Revenue beat(4)-62.02%
Max Revenue beat(4)2646.57%
Revenue beat(8)3
Avg Revenue beat(8)400.11%
Revenue beat(12)4
Avg Revenue beat(12)261.88%
Revenue beat(16)6
Avg Revenue beat(16)383.23%
PT rev (1m)2.02%
PT rev (3m)5.32%
EPS NQ rev (1m)0.66%
EPS NQ rev (3m)-12.41%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)-2.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-41.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)264.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 83.21
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.13
EYN/A
EPS(NY)-5.79
Fwd EYN/A
FCF(TTM)-3.67
FCFYN/A
OCF(TTM)-3.57
OCFYN/A
SpS0.72
BVpS-3.08
TBVpS-3.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.47%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.08%
ROA(5y)-38.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 125.81%
Cap/Sales 13.76%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.76
Quick Ratio 6.76
Altman-Z -1.38
F-Score3
WACC8.43%
ROIC/WACCN/A
Cap/Depr(3y)82.69%
Cap/Depr(5y)599.06%
Cap/Sales(3y)17.31%
Cap/Sales(5y)28.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.5%
EPS Next Y-8.98%
EPS Next 2Y-4.92%
EPS Next 3Y9.27%
EPS Next 5Y19%
Revenue 1Y (TTM)2633.99%
Revenue growth 3Y-35.98%
Revenue growth 5Y-7.24%
Sales Q2Q%26714.86%
Revenue Next Year2503.25%
Revenue Next 2Y553.56%
Revenue Next 3Y389.93%
Revenue Next 5Y243.66%
EBIT growth 1Y-8.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.12%
EBIT Next 3Y3.51%
EBIT Next 5Y24.98%
FCF growth 1Y-0.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.14%
OCF growth 3YN/A
OCF growth 5YN/A

CYTOKINETICS INC / CYTK FAQ

What is the fundamental rating for CYTK stock?

ChartMill assigns a fundamental rating of 2 / 10 to CYTK.


What is the valuation status of CYTOKINETICS INC (CYTK) stock?

ChartMill assigns a valuation rating of 0 / 10 to CYTOKINETICS INC (CYTK). This can be considered as Overvalued.


Can you provide the profitability details for CYTOKINETICS INC?

CYTOKINETICS INC (CYTK) has a profitability rating of 0 / 10.


Can you provide the financial health for CYTK stock?

The financial health rating of CYTOKINETICS INC (CYTK) is 3 / 10.